The global preclinical cro market is forecasted to grow by USD 3023.4 mn during 2025-2030, accelerating at a CAGR of 8.3% during the forecast period. The report on the global preclinical cro market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by regulatory modernization and industrialization of non-animal testing methodologies, ai-enabled discovery workflows and rise of autonomous predictive toxicology platform, specialized biologics and strategic growth of cell and gene therapy research.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope |
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 7.8% |
| CAGR | 8.3% |
| Incremental Value | $3023.4 mn |
Technavio's global preclinical cro market is segmented as below:
By End-User
- P and B companies
- Medical device companies
- Academic institutes
By Service
- Toxicology testing
- Bioanalysis and DMPK studies
- Compound management
- Others
By Application
- Oncology
- Neurology
- Cardiology
- Infectious diseases
- Others
Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the ai and reinforcement learning in early discovery workflows as one of the prime reasons driving the global preclinical cro market growth during the next few years. Also, human-centric microphysiological systems and organ-on-a-chip technology and strategic expansion of integrated multi-omics services and specialized oncology models will lead to sizable demand in the market.
The report on the global preclinical cro market covers the following areas:
- Global preclinical cro market sizing
- Global preclinical cro market forecast
- Global preclinical cro market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global preclinical cro market vendors that include Altasciences, AmplifyBio, BioEmission Technology Solutions, Charles River Laboratories, CYNBIOSE, Eurofins Scientific SE, Gempharmatech Co. Ltd., Global Center for Medical Innovation, ICON plc, Imavita S.A.S., IQVIA Holdings Inc., JSR Corp., Kunming Biomed International Ltd., Laboratory Corp., Medpace Holdings Inc., Parexel International Corp., Thermo Fisher Scientific Inc., Veeda Clinical Research Ltd., Vivotecnia, WuXi AppTec Co. Ltd.. Also, the global preclinical cro market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Service
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Preclinical CRO Market 2020 - 2024
- Historic Market Size - Data Table on Global Preclinical CRO Market 2020 - 2024 ($ million)
- 5.2 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.3 Service segment analysis 2020 - 2024
- Historic Market Size - Service Segment 2020 - 2024 ($ million)
- 5.4 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI in global preclinical CRO market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by End-user
- 8.1 Market segments
- 8.2 Comparison by End-user
- 8.3 P and B companies - Market size and forecast 2025-2030
- 8.4 Medical device companies - Market size and forecast 2025-2030
- 8.5 Academic institutes - Market size and forecast 2025-2030
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
9 Market Segmentation by Service
- 9.1 Market segments
- 9.2 Comparison by Service
- 9.3 Toxicology testing - Market size and forecast 2025-2030
- 9.4 Bioanalysis and DMPK studies - Market size and forecast 2025-2030
- 9.5 Compound management - Market size and forecast 2025-2030
- 9.6 Others - Market size and forecast 2025-2030
- 9.7 Market opportunity by Service
- Market opportunity by Service ($ million)
10 Market Segmentation by Application
- 10.1 Market segments
- 10.2 Comparison by Application
- 10.3 Oncology - Market size and forecast 2025-2030
- 10.4 Neurology - Market size and forecast 2025-2030
- 10.5 Cardiology - Market size and forecast 2025-2030
- 10.6 Infectious diseases - Market size and forecast 2025-2030
- 10.7 Others - Market size and forecast 2025-2030
- 10.8 Market opportunity by Application
- Market opportunity by Application ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 South Africa - Market size and forecast 2025-2030
- 12.6.6 Israel - Market size and forecast 2025-2030
- 12.6.7 Argentina - Market size and forecast 2025-2030
- 12.6.8 Colombia - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Regulatory modernization and industrialization of non-animal testing methodologies
- AI-enabled discovery workflows and rise of autonomous predictive toxicology platform
- Specialized biologics and strategic growth of cell and gene therapy research
- 13.2 Market challenges
- Geopolitical trade friction and fragmentation of global bio-service supply chains
- Convergence of ethical animal welfare mandates and high validation costs of alternative testing models
- Persistent shortage of specialized technical talent and impact of labor cost inflation
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- AI and reinforcement learning in early discovery workflows
- Human-centric microphysiological systems and organ-on-a-chip technology
- Strategic expansion of integrated multi-omics services and specialized oncology models
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Altasciences
- Altasciences - Overview
- Altasciences - Product / Service
- Altasciences - Key offerings
- SWOT
- 15.5 AmplifyBio
- AmplifyBio - Overview
- AmplifyBio - Product / Service
- AmplifyBio - Key offerings
- SWOT
- 15.6 BioEmission Technology Solutions
- BioEmission Technology Solutions - Overview
- BioEmission Technology Solutions - Product / Service
- BioEmission Technology Solutions - Key offerings
- SWOT
- 15.7 Charles River Laboratories
- Charles River Laboratories - Overview
- Charles River Laboratories - Business segments
- Charles River Laboratories - Key offerings
- Charles River Laboratories - Segment focus
- SWOT
- 15.8 CYNBIOSE
- CYNBIOSE - Overview
- CYNBIOSE - Product / Service
- CYNBIOSE - Key offerings
- SWOT
- 15.9 Eurofins Scientific SE
- Eurofins Scientific SE - Overview
- Eurofins Scientific SE - Business segments
- Eurofins Scientific SE - Key offerings
- Eurofins Scientific SE - Segment focus
- SWOT
- 15.10 Gempharmatech Co. Ltd.
- Gempharmatech Co. Ltd. - Overview
- Gempharmatech Co. Ltd. - Product / Service
- Gempharmatech Co. Ltd. - Key offerings
- SWOT
- 15.11 Global Center for Medical Innovation
- Global Center for Medical Innovation - Overview
- Global Center for Medical Innovation - Product / Service
- Global Center for Medical Innovation - Key offerings
- SWOT
- 15.12 ICON plc
- ICON plc - Overview
- ICON plc - Product / Service
- ICON plc - Key offerings
- SWOT
- 15.13 Imavita S.A.S.
- Imavita S.A.S. - Overview
- Imavita S.A.S. - Product / Service
- Imavita S.A.S. - Key offerings
- SWOT
- 15.14 IQVIA Holdings Inc.
- IQVIA Holdings Inc. - Overview
- IQVIA Holdings Inc. - Business segments
- IQVIA Holdings Inc. - Key offerings
- IQVIA Holdings Inc. - Segment focus
- SWOT
- 15.15 JSR Corp.
- JSR Corp. - Overview
- JSR Corp. - Business segments
- JSR Corp. - Key offerings
- JSR Corp. - Segment focus
- SWOT
- 15.16 Kunming Biomed International Ltd.
- Kunming Biomed International Ltd. - Overview
- Kunming Biomed International Ltd. - Product / Service
- Kunming Biomed International Ltd. - Key offerings
- SWOT
- 15.17 Laboratory Corp.
- Laboratory Corp. - Overview
- Laboratory Corp. - Business segments
- Laboratory Corp. - Key news
- Laboratory Corp. - Key offerings
- Laboratory Corp. - Segment focus
- SWOT
- 15.18 Medpace Holdings Inc.
- Medpace Holdings Inc. - Overview
- Medpace Holdings Inc. - Product / Service
- Medpace Holdings Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations